-
1.发明授权公开(公告)号：US09155783B2
公开(公告)日：2015-10-13
申请号：US11922148
申请日：2006-06-13
IPC分类号： A61K6/00 , A61K38/00 , A61K38/16 , A61K38/17 , A61K38/38 , A61K38/39 , A61K39/00 , C07K1/00 , C07K14/00 , C07K14/435 , C07K14/78
CPC分类号： C07K14/78 , A61K38/39 , A61K39/0011 , C07K14/77 , C07K2319/33 , C07K2319/40 , C12N2770/24211 , C12N2770/24234
摘要： This invention relates to the use of a polypeptide in the production of an immunostimulatory agent, said polypeptide comprising a sequence corresponding to the EDA domain of fibronectin, a fragment of the EDA domain which can bind to TLR4 or a variant of said EDA domain or a fragment which can bind to TLR4 and which has a homology of more than 70% with any form or natural fragment of the EDA domain. The invention also relates to the production methods and applications of said agent.
摘要翻译： 本发明涉及多肽在产生免疫刺激剂中的用途，所述多肽包含对应于纤连蛋白的EDA结构域的序列，EDA结构域的片段可结合TLR4或所述EDA结构域的变体或 片段，其可与TLR4结合并且与EDA结构域的任何形式或天然片段具有多于70％的同源性。 本发明还涉及所述试剂的制备方法和应用。
-
2.发明申请公开(公告)号：US20090220532A1
公开(公告)日：2009-09-03
申请号：US11922148
申请日：2006-06-13
CPC分类号： C07K14/78 , A61K38/39 , A61K39/0011 , C07K14/77 , C07K2319/33 , C07K2319/40 , C12N2770/24211 , C12N2770/24234
摘要： This invention relates to the use of a polypeptide in the production of an immunostimulatory agent, said polypeptide comprising a sequence corresponding to the EDA domain of fibronectin, a fragment of the EDA domain which can bind to TLR4 or a variant of said EDA domain or a fragment which can bind to TLR4 and which has a homology of more than 70% with any form or natural fragment of the EDA domain. The invention also relates to the production methods and applications of said agent.
摘要翻译： 本发明涉及多肽在产生免疫刺激剂中的用途，所述多肽包含对应于纤连蛋白的EDA结构域的序列，EDA结构域的片段可结合TLR4或所述EDA结构域的变体或 片段，其可与TLR4结合并且与EDA结构域的任何形式或天然片段具有多于70％的同源性。 本发明还涉及所述试剂的制备方法和应用。
-
3.发明授权公开(公告)号：US09657074B2
公开(公告)日：2017-05-23
申请号：US12160605
申请日：2006-02-23
申请人： Sylvie Bay , Teresa Freire , Claude Leclerc , Richard Lo-Man
发明人： Sylvie Bay , Teresa Freire , Claude Leclerc , Richard Lo-Man
CPC分类号： C07K14/4727 , A61K39/00 , A61K39/0011
摘要： The present invention relates to mucin glycoconjugates, and to a process of producing mucin glycoconjugates. It relates to the biological, pharmaceutical and medical applications thereof. The invention notably provides mucin glycoconjugates which do not require a protein carrier, such as KHL, to induce an immune response (anti-Tn IgG).
-
公开(公告)号：US20140378652A9
公开(公告)日：2014-12-25
申请号：US14005336
申请日：2012-03-16
申请人： Sylvie Bay , Claude Leclerc , Richard Lo-Man
发明人： Sylvie Bay , Claude Leclerc , Richard Lo-Man
IPC分类号： C07K9/00
CPC分类号： C07K9/00 , A61K47/481 , A61K47/48315 , A61K47/55 , A61K47/645 , C07K9/001 , C07K14/70539
摘要： The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)n(I) wherein M, T, B and n are as defined in claim 1.
-
5.发明授权Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof therapeutic uses thereof 有权插入腺苷酸环化酶蛋白或其片段的携带人乳头状瘤病毒表位的重组蛋白质的治疗用途公开(公告)号：US08637039B2
公开(公告)日：2014-01-28
申请号：US12977754
申请日：2010-12-23
IPC分类号： A61K39/12 , A61K39/295 , C07K14/235 , C07K14/025
CPC分类号： A61K39/385 , A61K45/06 , A61K2039/525 , A61K2039/6037 , C07K14/005 , C07K14/235 , C07K2319/00 , C12N7/00 , C12N9/88 , C12N2710/20022
摘要： The invention relates to a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several HPV antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells. It also concerns polynucleotides encoding the same. The recombinant protein or the polynucleotide can be used for the design of therapeutic means against HPV infection or against its malignant effects.
摘要翻译： 本发明涉及包含携带一个或多个HPV抗原的一个或多个表位的一个或几个多肽的重组蛋白，所述多肽插入腺苷酸环化酶（CyaA）蛋白或其片段的相同或不同的允许位点，其中 所述CyaA片段保留所述腺苷酸环化酶蛋白质的靶向抗原呈递细胞。 它也涉及编码相同的多核苷酸。 重组蛋白或多核苷酸可用于设计抗HPV感染或其恶性作用的治疗手段。
-
6.发明授权Modified ESAT-6 molecules and improved vaccine strains of Mycobacterium bovis BCG 有权改良的ESAT-6分子和改良的牛分枝杆菌BCG的疫苗株公开(公告)号：US08398991B2
公开(公告)日：2013-03-19
申请号：US11455929
申请日：2006-06-20
IPC分类号： A61K39/02
CPC分类号： C07K14/35 , A61K39/04 , A61K2039/522 , C07K2319/20
摘要： A genetically modified strain of M. tuberculosis or Mycobacterium bovis BCG is provided, wherein the genetically modified strain comprises at least one modified sequence comprising SEQ ID NO: 1, SEQ ID NO: 2, or both, having at least one mutation at T2, Q4, F8, A14, L28, L29, W43, G45, Y51, Q55, Q56, N66, M83, V90, M93, or F94 in SEQ ID NO:1; or at least one mutation at Q3, F7 A13, L27, W42, G44, Y50, Q54, N65, N67, M82, V89, M92, or F93 in SEQ ID NO:2, or a deletion at the terminal end of less than 20 amino acids. In a preferred embodiment, the mutation is at least one of T2H, Q4L, F8I, AI4R, L28A, L29S, W43R, G45T, Q55I, Q56A, N66I, N67A, M83I, V90R, M93T, or F94Q in SEQ ID NO:1, and Q3L, F7I, A13R, L27A, L28S, W42R, Q44T, Q54I, N65I, M82I, V89R, M92T, and F93Q in SEQ ID NO:2. Similarly, the genetically modified strain may also secrete ESAT-6 with a hexa-histidine tag, tetra-cysteine tag, or FLAG-tag, a GFP-fusion, or a short truncation at the C-terminal end of less than 20 amino acids.
摘要翻译： 提供结核分枝杆菌或牛分枝杆菌BCG的遗传修饰菌株，其中所述遗传修饰菌株包含至少一个包含SEQ ID NO：1，SEQ ID NO：2或两者的经修饰的序列，或在T2处具有至少一个突变， SEQ ID NO：1中的Q4，F8，A14，L28，L29，W43，G45，Y51，Q55，Q56，N66，M83，V90，M93或F94; 或SEQ ID NO：2中的Q3，F7A13，L27，W42，G44，Y50，Q54，N65，N67，M82，V89，M92或F93的至少一个突变，或末端的缺失小于 20个氨基酸。 在优选实施方案中，突变是SEQ ID NO：1中的T2H，Q4L，F8I，AI4R，L28A，L29S，W43R，G45T，Q55I，Q56A，N66I，N67A，M83I，V90R，M93T或F94Q中的至少一种 ，以及SEQ ID NO：2中的Q3L，F7I，A13R，L27A，L28S，W42R，Q44T，Q54I，N65I，M82I，V89R，M92T和F93Q。 类似地，遗传修饰的菌株也可以分泌具有六组氨酸标签，四半胱氨酸标签或FLAG标签的ESAT-6，GFP-融合物或C末端的短截短小于20个氨基酸 。
-
7.发明授权Identification of virulence associated regions RD1 and RD5 leading to improve vaccine of M. bovis BCG and M. microti 失效鉴定毒力相关区域RD1和RD5，导致改进牛分枝杆菌BCG和M. microti的疫苗公开(公告)号：US07883712B2
公开(公告)日：2011-02-08
申请号：US10510021
申请日：2003-04-01
申请人： Stewart Cole , Alexander S. Pym , Roland Brosch , Priscille Brodin , Laleh Majlessi , Caroline Demangel , Claude Leclerc
发明人： Stewart Cole , Alexander S. Pym , Roland Brosch , Priscille Brodin , Laleh Majlessi , Caroline Demangel , Claude Leclerc
CPC分类号： A61K39/04 , A61K39/00 , A61K2039/522 , A61K2039/523 , C07K14/35 , C12N1/36 , C12Q1/689 , G01N33/5695
摘要： The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli, especially the ESAT-6 and CFP-10 genes. These strains will be referred as the M bovis BCG::RDI or M. microti::RD1 strains and are useful as a new improved vaccine for preventing tuberculosis and as a therapeutical product enhancing the stimulation of the immune system for the treatment of bladder cancer. These strains are also useful for the expression and presentation of heterologous antigens and molecule that are of therapeutic or prophylactic interest.
摘要翻译： 本发明涉及牛分枝杆菌BCG或微生物菌株，其中所述菌株具有整合部分或全部RD1区域，其负责增强结核杆菌的免疫原性，特别是ESAT-6和CFP-10基因。 这些菌株将被称为牛分枝杆菌BCG :: RDI或M.microti :: RD1菌株，并且可用作用于预防结核病的新型改良疫苗和作为增强刺激免疫系统用于治疗膀胱癌的治疗产品 。 这些菌株也可用于表达和呈递具有治疗或预防兴趣的异源抗原和分子。
-
8.发明申请RECOMBINANT ADENYLATE CYCLASE TOXIN OF BORDETELLA INDUCES T CELL RESPONSES AGAINST TUMORAL ANTIGENS 审中-公开BORDETELLA的重组腺苷酸环化酶诱导针对肿瘤抗原的T细胞应答公开(公告)号：US20100310594A1
公开(公告)日：2010-12-09
申请号：US12731196
申请日：2010-03-25
申请人： Gilles Dadaglio , Claude Leclerc , Daniel Ladant , Benoit Van Den Eynde , Sandra Morel , Cecile Bauche
发明人： Gilles Dadaglio , Claude Leclerc , Daniel Ladant , Benoit Van Den Eynde , Sandra Morel , Cecile Bauche
CPC分类号： F16C33/7886 , A61K38/164 , A61K39/0011 , A61K39/099 , A61K39/39 , A61K47/6415 , A61K47/646 , A61K2039/6037 , A61K2039/6068 , C12N9/88 , C12Y406/01001 , F16C25/083
摘要： An immunogenic composition comprising a recombinant protein comprising a Bordetella CyaA, or a fragment thereof, and a peptide that corresponds to a tumor antigen is provided as a cancer treatment. Methods of treatment with this immunogenic composition are also provided. In an embodiment, the therapeutic composition is a treatment for melanoma, and comprises epitopes from the HLA*0201 epitope. These epitopes include Tyr or GnT-V, and are present in the recombinant proteins CyaA-E5-Tyr and CyaA-E5-GnT-V.
摘要翻译： 作为癌症治疗，提供了含有包含Bordetella CyaA或其片段的重组蛋白质和对应于肿瘤抗原的肽的免疫原性组合物。 还提供了用该免疫原性组合物治疗的方法。 在一个实施方案中，治疗组合物是黑素瘤的治疗，并且包含来自HLA * 0201表位的表位。 这些表位包括Tyr或GnT-V，并且存在于重组蛋白CyaA-E5-Tyr和CyaA-E5-GnT-V中。
-
9.发明申请Recombinant protein carrying human papillomavirus epitopes inserted in an adenylate cyclase protein or fragment thereof. therapeutic uses thereof 有权携带人乳头状瘤病毒表位的重组蛋白质插入腺苷酸环化酶蛋白或其片段。 其治疗用途公开(公告)号：US20070072266A1
公开(公告)日：2007-03-29
申请号：US11517313
申请日：2006-09-08
CPC分类号： A61K39/385 , A61K45/06 , A61K2039/525 , A61K2039/6037 , C07K14/005 , C07K14/235 , C07K2319/00 , C12N7/00 , C12N9/88 , C12N2710/20022
摘要： The invention relates to a recombinant protein comprising one or several polypeptides bearing one or several epitopes of one or several HPV antigens, said polypeptides being inserted in the same or different permissive sites of an adenylate cyclase (CyaA) protein or of a fragment thereof, wherein said CyaA fragment retains the property of said adenylate cyclase protein to target Antigen Presenting Cells. It also concerns polynucleotides encoding the same. The recombinant protein or the polynucleotide can be used for the design of therapeutic means against HPV infection or against its malignant effects.
摘要翻译： 本发明涉及包含携带一个或多个HPV抗原的一个或多个表位的一个或几个多肽的重组蛋白，所述多肽插入腺苷酸环化酶（CyaA）蛋白或其片段的相同或不同的允许位点，其中 所述CyaA片段保留所述腺苷酸环化酶蛋白质的靶向抗原呈递细胞。 它也涉及编码相同的多核苷酸。 重组蛋白或多核苷酸可用于设计抗HPV感染或其恶性作用的治疗手段。
-
10.发明申请Modified ESAT-6 molecules and improved vaccine strains of Mycobacterium bovis BCG 有权改良的ESAT-6分子和改良的牛分枝杆菌BCG的疫苗株公开(公告)号：US20070009547A1
公开(公告)日：2007-01-11
申请号：US11455929
申请日：2006-06-20
CPC分类号： C07K14/35 , A61K39/04 , A61K2039/522 , C07K2319/20
摘要： A genetically modified strain of M. tuberculosis or Mycobacterium bovis BCG is provided, wherein the genetically modified strain comprises at least one modified sequence comprising SEQ ID NO: 1, SEQ ID NO: 2, or both, having at least one mutation at T2, Q4, F8, A14, L28, L29, W43, G45, Q55, Q56, N66, M83, V90, M93, or F94. In a preferred embodiment, the mutation is at least one of T2H, Q4L, F8I, A14R, L28A, L29S, W43R, G45T, Y51, Q55I, Q56A, N66I, N66A, M83I, V90R, M93T, or F94Q. Similarly, the genetically modified strain may also secrete ESAT-6 with a a histidine tag, tetra-cysteine tag or FLAG-tag, a GFP-fusion, or a short truncation at the C-terminal end of less than 20 amino acids.
摘要翻译： 提供结核分枝杆菌或牛分枝杆菌BCG的遗传修饰菌株，其中所述遗传修饰菌株包含至少一个包含SEQ ID NO：1，SEQ ID NO：2或两者的经修饰的序列，或在T2处具有至少一个突变， Q4，F8，A14，L28，L29，W43，G45，Q55，Q56，N66，M83，V90，M93或F94。 在优选的实施方案中，突变是T2H，Q4L，F8I，A14R，L28A，L29S，W43R，G45T，Y51，Q55I，Q56A，N66I，N66A，M83I，V90R，M93T或F94Q中的至少一种。 类似地，遗传修饰的菌株也可以在小于20个氨基酸的C末端分泌具有组氨酸标签，四半胱氨酸标签或FLAG标签，GFP融合物或短截短的ESAT-6。
-
-
-
-
-
-
-
-
-
搜索结果
45 条记录 (耗时 0.042 秒)
